Archive: 2023 CML Publications

2023 Clinical Papers

December

CML and the WHO: Why?
Berman E et al. J Clin Oncol, December 2023

Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with CML
Winn AN et al. JAMA Netw Open, December 2023
open access publication

Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a Report from the BCR::ABL1 Pathology Group
Rivera D et al. Mod Pathol, December 2023
open access publication

Accelerated-phase CML: de novo and transformed
Shanmunagathan N and Hughes TP. Hematology Am Soc Hematol Educ Program, December 2023
open access publication

Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥ 2 tyrosine kinase inhibitors: a systematic literature review
Atallah E et al. Ther Adv Hematol, December 2023
open access publication

Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML Working Group) – in French
Réa D et al. Bull Cancer, December 2023
open access publication

Resistance mutations in CML and how we approach them - Review
Soverini S et al. Hematology Am Soc Educ Program, December 2023
open access publication

SOHO State of the art updates and next questions: Chronic myeloid leukemia and pregnancy: Per Aspera ad Astra” - Review
Abruzzese E et al. Clin Lymphoma Myeloma Leuk, December 2023

How to improve treatment-remission eligibility in CML? Review
Costa A and Breccia M. Br J Haematol, December 2023
open access publication

The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
Liu L et al. Hematology, December 2023
open access publication

Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy, The Surveillance, Epidemiology, and End Results database, 2000-2019
Sasaki K et al. Cancer, December 2023

Sex-specific incidence of hepatitis B virus flares among BCR-ABL tyrosine kinase inhibitor users in Taiwan
Wang LY et al. Pharmacoepidemiol Drug Saf, December 2023

Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans
Hofmann J et al. Leukemia, December 2023
open access publication

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
Kongruang A et al. Hematology, December 2023
open access publication

An update of the management of advanced phase chronic myeloid leukemia – Review
Short NJ et al. Curr Hematol Malig Rep, December 2023

Evaluation of real-world versus clinical trial outcome of tyrosine kinase inhibitor therapy for chronic myeloid leukemic
Collins JB et al. J Oncol Pharm Pract, December 2023
open access publication

Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: Clinical relevance, impact on outcome, preventive measures and treatment strategies – Review
Iurlo A et al. Curr Treat Options Oncol, December 2023

Exploration of treatment-free remission in CML, based on molecular monitoring – Review
Zhang Z et al. Cancer Med, December 2023
open access publication

November

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
Cross NCP et al. Leukemia, November 2023
open access publication

Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study
Zambrotta GPM et al. Am J Hematol, November 2023
open access publication

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: Results from the phase 4 BYOND study
Rosti G et al. Leukemia, November 2023
open access publication

Survival with chronic myeloid leukemia after failing milestones
Lauseker M et al. Leukemia, November 2023
open access publication

What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia?
Kantarjian HM Leukemia, November 2023

The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib
Mulas O et al. Ann Hematol, November 2023

Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
Park H et al. Ther Adv Hematol, November 2023
open access publication

Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients
Rafiq Mohammed A et al. Gene, November 2023

October

Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review
Aldapt MB et al. Oncology, October 2023

Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network analysis – Review
Zhang S et al. Expert Opin Drug Saf, October 2023

Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions
Larfors G et al. Eur J Haematol, October 2023
open access publication

Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy
Khadadah FM et al. Leuk Res, October 2023

Revisiting six established practices in the treatment of chronic myeloid leukemia - Review
Kantarjian HM et al. Lancet Haematol, October 2023

Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results
Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023

Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report
Alshurufa A et al. Case Rep Oncol, October 2023
open access publication

Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
Efficace F et al. Cancer, October 2023

September

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Kok CH et al. Blood Cancer J, Sept 2023
open access publication

Survival with chronic myeloid leukemia after failing milestones
Lauseker M et al. Leukemia, September 2023
open access publication

Treatment-free remission after dasatinib in patients with chronic myeloid leukemia in chronic-phase with deep molecular response: Final 5-year analysis of DASFREE
Shah NP et al. Br J Haematol, Sept 2023
open access publication

The (near) miracle of therapy in chronic myeloid leukemia
Radich JP. Br J Haematol, Sept 2023
open access publication

Improvement, implementation, and evaluation of the CMyLife Digital Care Platform: Participatory Action Research Approach
Verweij L et al. J Med Internet Res, Sept 2023
open access publication

BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
Kockerols C et al. Eur J Haematol, Sept 2023

External validation of the predictive scoring systems for molecular responses in chronic myeloid leukemia receiving initial imatinib therapy
Qi F et al. Leukemia, Sept 2023

Final report of TKI discontinuation trial with dasatinib for the second attempts of treatment-free remission after failing the first attempts with imatinb: Treatment-free Remission Accomplished by Dasatinib (TRAD) Study
Perusini MA et al. Br J Haematol, Sept 2023

Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukemia
Del Rosario García B et al. J Oncol Pharm Pract, Sept 2023

The expanding CML treatment landscape: an introspective commentary
Lipton JH, Blood Cancer J, Sept 2023
open access publication

Bilateral massive retinal infiltrates: Sign of blast crisis in chronic myeloid leukemia
Patel A et al. Ophthalmology, Sept 2023

Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice
Ielo C et al. Leuk Lymphoma, Sept 2023

Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase
Oyogoa E et al. Front Oncol, Sept 2023
open access publication

Single cells tell multiple tales in CML
Ross DM. Blood, June 2023
open access publication

Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestone in CML
Murkoviç M et al. Pathol Res Pract, June 2023

BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells
Artus J et al. Exp Hematol, June 2023

Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia – Review
Dekker SE et al. Am Soc Clin Oncol Educ Book, June 2023
open access publication

Chronic myeloid leukemia during pregnancy with placental involvement: Case Report and Literature Review
Çobankent Aytekin E et al. Fetal Pediatr Pathol, June 2023

May

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S and Cortes J. Haematologica, April 2023
open access publication

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
Pavlovsky C et al. J Hematol Oncol, April 2023
open access publication

Cardiovascular risk in chronic myeloid leukemia: A multidisplinary consensus on screening and management
Milojkovic D et al. Eur J Haematol, April 2023
open access publication

Gene expression pattern of ESPL1, PTTG1 and PTTG1IP can potentially predict response to TKI first-line treatment of patients newly diagnosed CML
Christiani E et al. Cancers(Basel), May 2023
open access publication

A pragmatic approach to managing long-term adverse effects in chronic myeloid leukemia treatment - Review
Lucero JA and Lipton JH. Curr Hematol Malig Rep, May 2023

The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist - Review
Clements J et al. Future Oncol, May 2023
open access publication

SOHO state of the art updates and next questions / Update on treatment-free-remission in chronic myeloid leukemia (CML) - Review
Mikhaeel S and Atallah E. Clin Lymphoma Myeloma Leuk, May 2023

Imatinib compared to second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
Yang S et al. Am J Hematol, May 2023
open access publication

Response-based dosing for ponatinib: Model-based analyses of the dose-ranging OPTIC study
Hanley MJ et al. Clin Pharmacol Ther, May 2023

Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review
Ali Hailan YM et al. Oncology, May 2023
open access publication

A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
Kaddoura R et al. Front Med, May 2023
open access publication

Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplant - Review
Uhm J. Blood Res, April 2023
open access publication

Developing therapeutic approaches for CML: a review
Kumar V et al. Mol Cell Biochem, May 2023

The EMA assessment of Asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors
Tesileanu CMS et al. Oncologist, May 2023
open access publication

Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase focusing on age and dose effects
Tokuhira M et al. Int J Hematol, May 2023

Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!
Eskazan AE et al. Cancer, May 2023

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response
Tossoni L et al. Ann Hematol, May 2023

April

The outcome of post-transplant asciminib in patients with CML
Fernando F et al. Bone Marrow Transplant, April 2023

Management of chronic myeloid leukemia in 2023 – Common ground and common sense - Review
Senapati J et al. Blood Cancer J, April 2023
open access publication

Efficacy and safety of nilotinib in chronic myeloid leukemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study
Dulucq S et al. Br J Haematol, April 2023
open access publication

Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event
Tarantini F et al. Leuk Res, April 2023

Managing women of childbearing age with chronic myeloid leukemia: Safety and treatment considerations
Expert Rev Hematol, April 2023

An analysis of dasatinib treatment patterns in patients with chronic myeloid leukemia after experiencing pleural effusion during dasatinib therapy
McBride A et al. Acta Haematol, April 2023

Efficacy and safety of nilotinib as frontline therapy in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
Luciano L et al. Ann Hematol, April 2023
open access publication

Applications of machine learning in chronic myeloid leukemia - Review
Elhadary M et al. Diagnostics(Basel), April 2023
open access publication

Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting
Yilmaz R et al. Future Oncol, April 2023

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia – Review
Han JJ et al. Blood Res, April 2023
open access publication

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings - Review
Cheng F et al. Front Oncol, April 2023
open access publication

Assessment of imatinib as a primary treatment of chronic myeloid leukemia in chronic phase: a Cohort Study
Merin D et al. J Oncol Pharm Pract, April 2023

March

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Hochhaus A et al. Leukemia, March 2023
open access publication

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Mauro MJ et al. Leukemia, March 2023
open access publication

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Shanmunagathan N et al. Haematologica, March 2023
open access publication

Editorial: Advances in the treatment of chronic myeloid leukemia
Eskazan AE et al. Front Oncol, March 2023
open access publication

High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population
Kockerols CCB et al. Haematologica, March 2023
open access publication

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis RM et al. Blood Adv, March 2023
open access publication

The economic burden of chronic myeloid leukemia in patients with later lines: Findings from a real-world analysis in Italy
Breccia M et al. Adv Ther, March 2023
open access publication

A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia
Krishnan V et al. Blood, March 2023

Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian Medicines Agency (AIFA)
Breccia M et al. Ann Hematol, March 2023

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
Walia A and Prasad V. Blood Cancer J, March 2023
open access publication

Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia
Aleem A et al. Int J Hematol, March 2023

Association between bariatric surgery and outcomes in chronic myeloid leukemia
Haddad FG et al. Cancer, March 2023

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase – Review
Choi EJ. Blood Res, March 2023
open access publication

Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO study): study protocol for prospective, multicentre, single-arm trial
Djodikromo MF et a. BMC Cancer, March 2023
open access publication

February

Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
Tsubaki M et al. BMB Rep, February 2023
open access publication

Repurposing the Bis-Biguanide Alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia
Muselli F et al. Cancers(Basel), February 2023
open access publication

Discovery of CZS-241: A potent, selective, and orally available Polo-like kinase 4 inhibitor for the treatment of CML
Sun Y et al. J Med Chem, February 2023

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
Jiang B et al. Front Oncol, February 2023
open access publication

A survey of patient experience in CML: American and Canadian Perspectives
Hillis C et al. Patient Prefer Adherence, February 2023
open access publication

Importance of tyrosine kinase inhibitor treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-Free study
Yoshida C et al. Int J Hematol, February 2023
open access publication

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network
Nunes RAB et al. Front Cardiovasc Med, February 2023
open access publication

Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison
Hyland KA et al. Leuk Lymphoma, February 2023

Family planning and pregnancy in patients with chronic myeloid leukemia – Review
Berman E et al. Curr Hematol Malig Rep, February 2023

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modelling and pathway analysis
Radich JP et al. Haematologica, February 2023
open access publication

January

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in CML
Irani YD et al. Blood Adv, January 2023
open access publication

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
Zhang H et al. Haematologica, January 2023
open access publication

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
Häselbarth L et al. Cancer Immunol Immunother, January 2023
open access publication

mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells
Panuzzo C et al. Int J Mol Sci, January 2023
open access publication

BH3 mimetics and TKI combined therapy for CML
Brumatti G et al. Biochem, January 2023
open access publication

Differential inhibition of T cell receptor and STAT5 signalling pathways determine the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
Harrington P et al. Haematologica, January 2023
open access publication

2023 Scientific Papers

December

Precision isolation of circulating leukemia cells in chronic myelogenous leukemia patients using a novel microfluid device and its clinical applications
Ouyaung D et al. Cancers(Basel), December 2023
open access publication

Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis
Wu A et al. Leukemia, December 2023

The SNP rs460089 in the gene promoter of the drug-transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Machova Polakova K et al. Leukemia, December 2023
open access publication

A review on characterization of BCR-ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes
Zenebe B et al. Hematology Review, December 2023
open access publication

C-Myc inhibition intensified the anti-leukemic properties of imatinib in chronic myeloid leukemia cells
Zehtabcheh S et al. Mol Biol Rep, December 2023

The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTor signaling pathway in chronic myeloid leukemia
Liu XY et al. Hematology, December 2023
open access publication

Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia
Yin L et al. Hematology, December 2023
open access publication

miR-181a plays a tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1
Zhang X et al. Cell Mol Life Sci, December 2023
open access publication

Osimertinib covalently binds to CD34 and eliminates progenitor cells
Xia L et al. Cancer Res, December 2023

Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells
Yang Y et al. Hematology, December 2023
open access publication

November

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Huuhtanen J et al. Leukemia, November 2023
open access publication

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
Shin JE et al. Mol Cancer, November 2023
open access publication

Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
Häselbarth L et al. BMC Cancer, November 2023
open access publication

October

Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review
Verhagen NE et al. Pharmaceutics, October 2023
open access publication

Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia
Han H et al. Biochem Pharmacol, October 2023

A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
Zhang X et al. Cell Mol Biol Lett, October 2023
open access publication

AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells
Lapa BS et al. Int J Mol, October 2023
open access publication

Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis
Boucher L et al. Int J Mol, October 2023
open access publication

September

New patterns of genetic instability in chronic myeloid leukemia: Interesting, but not ready for clinical use
Schiffer CA. Haematologica, Sept 2023
open access publication

Aquired miR-142 deficit in leukemia stem cells suffices to drive chronic myeloid leukemia into blast crisis
Zhang B et al. Nat Commun, Sept 2023
open access publication

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
Okabe S and Gotoh A. BMC Cancer, Sept 2023

The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on TKI therapy predicts the imatinib treatment failure
Ratajczak B et al. Leuk Res, Sept 2023
open access publication

MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review
Sing P. Med Oncol, Sept 2023

August

Using natural killer cell-derived exosomes as a cell-free therapy for leukemia
Samara A et al. Hematol Oncol, August 2023

NDRG3 regulates imatinib resistance by promoting ß-catenin accumulation in the nucleus in chronic myelogenous leukemia
Wang X et al. Oncol Rep, August 2023
open access publication

Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia
Martínez-Castillo M et al. Leuk Res, August 2023

Mitochondrial dysfunction in cardiotoxicity induced by BCR-ABL1 tyrosine kinase inhibitors – underlying mechanisms, detection, potential therapies – Review
Sun S et al. Cardiovasc Toxicol, August 2023

Crizotinib acts as a ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL T315I and BCR-ABL1 T315I-E255K
Mian AA et al. Ann Hematol, August 2023
open access publication

MEK1/2 regulates normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
Mazzera L et al. Leukemia, August 2023
open access publication

High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
Aghel N et al. Leuk Lymphoma, August 2023

Food for thought (and CML survival)
Sezaki M and Huang G. Blood, August 2023

Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells
Rattigan KM et al. Nat Commun, August 2023
open access publication

The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associations with each resistance mechanisms
Leow BCS et al. Sci Rep, Aug 2023
open access publication

July

Genetic separation of chronic myeloid leukemia stem cells from normal hematopietic stem cells at single-cell resolution
Chen Y et al. Leukemia, July 2023
open access publication

Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukemia stem cells
Rattigan KM et al. EMBO Rep, July 2023
open access publication

Profiling of miRNAs and their interfering targets in peripheral blood mononuclear from patients with chronic myeloid leukemia
Wu SC et al. Front Oncol, July 2023
open access publication

Control of PH+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors
Ansari S and Verma M. Med Oncol, July 2023

HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway
Yin L et al. Hum Cell, July 2023

Phenotypic and functional characterization of subpopulation of imatinib resistant chronic myeloid leukemia cell line
Hekmatshoar Y et al. Adv Med Sci, July 2023 (epub ahead of print)

Histone demethylase PHF8 facilitates the development of chronic myeloid leukemia by directly targeting BCR::ABL1
Feng H et al. Br J Haematol, July 2023
open access publication

June

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
Radich JP et al. Haematologica, June 2023
open access publication

Project Confirm: Accelerated drug approvals for chronic myeloid leukemia
Sweet KL et al. Clin Cancer Res, June 2023

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
Tribelli M et al. Cancer, June 2023
open access publication

Management of chronic myeloid leukemia patients in later lines: The role of ponatinib and new compounds - Review
Scalzulli E et al. Clin Lymphoma Myeloma Leuk, June 2023

Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress
Kantarjian HM and Tefferi A. Am J Hematol, June 2023
open access publication

Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey
Chen H et al. Leuk Lymphoma, June 2023

Switching from imatinib to nilotinib plus pegylated interferon α2b in chronic phase chronic myeloid leukemia failing to achieve deep molecular response: clinical and immunologica effects
Geelen IGP et al. Ann Hematol, June 2023

Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulation surviving
Yin SS et al. Cell Cycle, June 2023
open access publication

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukemia cells
Tsubaki M et al. Cell Prolif, June 2023
open access publication

May

Modulating retinoid-x-receptor alpha RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
Rajmani BM et al. Front Pharmacol, May 2023
open access publication

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
Langhammer M et al. Leukemia, May 2023
open access publication

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Hiroshi H et al. Sci Rep, May 2023
open access publication

Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
Qiu S et al. Blood, May 2023

Frequency and driver mutation diversity in concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm
Langabeer SE et al. Int J Hematol, April 2023

Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A.
Xu Y et al. Cancer, May 2023
open access publication

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
Gao C et al. Front Pharmacol, April 2023
open access publication

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
Mitrovsky O et al. PLoSOne, May 2023
open access publication

Modeling global genomic instability in chronic myeloid leukemia (CML) using patient-derived induced pluripotent stem cells (iPSCs)
Telliam G et al. Cancers(Basel), May 2023
open access publication

April

New patterns of genetic instability in chronic myelogenous leukemia: interesting, but not ready for clinical use
Schiffer CA. Haematologica, April 2023
open access publication

The structure of the hematopoietic system can explain chronic myeloid leukemia progression
Pérez-Jiménez M et al. Sci Rep, April 2023
open access publication

Characterization of bone marrow niche in chronic myeloid leukemia patients identifies CXCL14 as a new therapeutic option
Polinska M et al. Blood, April 2023

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
Fiordi B et al. Haematologica, April 2023
open access publication

Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia
Zhong FM et al. Cancer Cell Int, April 2023
open access publication

March

AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells
Lee YC et al. Biochem Pharmacol, March 2023

The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere lengths in chronic myeloid leukemia
Deregowska A et al. J Cancer Res Clin Oncol, March 2023
open access publication

Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame imatinib-resistance in CML CD34+ cells
Xu X et al. Cell Commun Signal, March 2023
open access publication

Imatinib blocks tyrosine phosphorylation of Smad4 and restores TFG-ß growth-suppressive signaling in BCR-ABL1-positive leukemia
Wang L et al. Signal Transduct Target Ther, March 2023
open access publication

The prognostic and therapeutic potential of HO-1 in leukemia and MDS – Review
Sadeghi M et al. Cell Commun Signal, March 2023
open access publication

NOX2 and NOX4 control mitochondrial function in chronic myeloid leukemia
Romo-González M et al. Free Radic Biol Med, March 2023
open access publication

TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN
Qiu Q et al. Signal Transduct Target Ther, March 2023
open access publication

Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Kaehler M and Cascorti I. Handb Exp Pharmacol, March 2023

February

Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for the novo lymphoid blast phase-chronic myeloid leukemia
Yang Z et al. Leuk Res, February 2023

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanism, and clinical management strategies – Review
Cheng F et al. Front Oncol, February 2023
open access publication

Cardiovascular toxicities associated with tyrosine kinase inhibitors - Review
Sahegh N et al. Curr Cardiol Rep, February 2023

The bone marrow immune environment in CML: Treatment responses, treatment-free remission and therapeutic vulnerabilities
Patterson SD & Copland M. Curr Hematol Malig Rep, February 2023
open access publication

January

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Hochhaus A et a. Leukemia, January 2023
open access publication

Matching adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E et al. J Caner Res Clin Oncol, January 2023
open access publication

Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet!
Radich J. Am J Hematol, January 2023
open access publication

Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor
Bidikian A et al. Am J Hematol, January 2023

The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
Jabbour EJ et al. Am J Hematol, January 2023

A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): Can it be applied in clinical practice? - Review
Çiftçiler R et al. Clin Lymphoma Myeloma Leuk, January 2023

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring
Bataller A et al. Leuk Lymphoma, January 2023

Is it time to reconsider molecular response milestones in CML?
Walia A and Prasad V. Am J Hematol, January 2023

2023 Low- and Middle-Income Countries Publications

Worldwide Publications of Interest

Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings
Hailu S et al. Ann Hematol, May 2023
open access publication

CML Publications from Africa

A study to explore the role of IDH1 (R132) mutation on imatinib toxicity and effect of ABCG2/OCT1 expression on N-Desmethyl imatinib plasma level in Egyptian chronic myeloid leukemia patients
Sabri A et al. Drug Res (Stuttg.), March 2023

CML Publications from the Middle East

Long-term results of imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: National Multicenter perspective study
Savaç EM et al. Turk J Haematol, October 2023
open access publication

Assessment of regulatory T cells (Tregs) and Foxp3 methylation level in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy
Sabir SF et al. Immunogenetics, April 2023

ENOX2 NADH Oxidase: A BCR-ABL1-dependent cell surface and secreted Redox protein in chronic myeloid leukemia (CML)
Baykal-Köse S et al. Turk J Haematol, April 2023
open access publication

CML Publications from Asia

Population pharmacokinetics and pharmacogenetics analyses of dasatinib in Chinese patients with chronic myeloid leukemia
He S et al. Pharm Res, Sept 2023

Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution
Chethan R et al. Ann Hematol, June 2023

Long-term outcomes of frontline imatinib therapy for CML in China
Cheng F et al. Front Oncol, May 2023
open access publication

Feasibility of treatment-free remission with generic imatinib:
Results of generic imatinib-free trial-in-chronic myeloid leukemia-chronic phase study
Goni D et al. Indian J Med Res, January 2023
open access publication

Efficacy of flumatinib in CML patients with F359V/C mutation
Gao H et al. Indian J Hematol Transfus, Apr 2023

Response to Tyrosine Kinase Inhibitors in Patients with BCR-ABL1 Positive Chronic Myeloid Leukemia; 13.5 Years’ Experience at Patan Hospital, Nepal
Adhikari A. et al. Blood Res. Rev. March 2023
open access publication

Effect of imatinib treatment on renal anaemia in chronic myeloid leukemia patients
Singh AK et al. J Oncol Pharm Pract, March 2023

Attenuated dose dasatinib in newly diagnosed chronic myeloid leukemia chronic phase patients in India
Ahmed R et al. Clin Lymphoma Myeloma Leuk, February 2023

Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects
Wang Y et al. Expert Opin Investig Drug, February 2023

Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca2+-dependent gap junction intercellular communication
Liu X et al. Chin Med J (Engl.), February 2023
open access publication

Supplemental pioglitazone to patients of CML with suboptimal TKI response: A pragmatic pilot study
Yanamandra U et al. Indian J Hematol Blood Transfus, January 2023

OCT-1 expression in patients with chronic myeloid leukemia: A comparative analysis with respect to imatinib treatment
Bozhurt Bulakci B et al. Indian J Hematol Blood Transfus, Oct 2023

CML Publications from Latin America

Long-term follow-up in patients with chronic myeloid leukemia treated with ponatinib in a real-world cohort: Safety and efficacy analysis
Mela Osorio MJ et al. Clin Lymphoma Myeloma Leuk, October 2023

2023 COVID-19 and CML Publications

Papers on COVID-19 and CML

Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era
Qi F et al. Ann Hematol, August 2023

SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukemia
Cheng F et al. J Cancer Res Clin Oncol, June 2023

The impact of COVID-19 in patients with chronic myeloid leukemia – a nationwide population-based study
Dahlén T et al. Leukemia, April 2023
open access publication

Papers on COVID-19 vaccines and CML

Regular humoral and cellular immune responses in individuals with chronic myeloid leukemia who received a full vaccination schedule against COVID-19
Rodríguez-Mora S et al. Cancers(Basel), October 2023
open access publication

Papers on COVID-19 and hematological malignancies

Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference of Infections in Leukemia (ECIL 9)
Cesaro S et al. Leukemia, July 2023
open access publication

2023 Pediatric CML Publications

Bosutinib: Pediatric first approval
Hoy SM et al. Paediatr Drugs, Dec 2023

Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia
Toker M et al. Pediatr Dermatol, Dec 2023

Treatment and follow-up of children with CML-CP in the TKI era - Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort
Roy Moulik N et al. Br J Haematol, Dec 2023

Chronic myeloid leukemia (CML) in children and adolescents - Clinicopathological findings
Nevejan L et al. Eur J Haematol, Nov 2023

Physiologically based pharmacokinetics modelling of nilotinib for drug-drug interactions, pediatric patients, and pregnancy and lactation
Liu XI et al. J Clin Pharmacol, Nov 2023

Continuous therapy response references for BCR::ABL1 in pediatric chronic myeloid leukemia
Volz C et al. Sci Rep, Oct 2023
open access publication

Somatic variant profiling in chronic phase pediatric CML
Behrens YL et al. Haematologica, Sept 2023
open access publication

The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
Hijiya N et al. Blood Adv, Sept 2023

Priapism at diagnosis of pediatric chronic myeloid leukemia: Data derived from a large cohort of children and teenagers and a narrative review on priapism management
Suttorp M et al. J Clin Med, July 2023
open access publication

Chronic myeloid leukemia in children and adolescents
Gotesman M et al. Adv Pediatr, Aug 2023

Effect of imatinib mesylate and growth in pediatric CML: A systematic review and meta-analysis
Gupta P et al. J Pediatr Hematol Oncol, July 2023

Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults
Mersin S et al. Expert Opin Pharmacother, July 2023

Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase CML in the tyrosine kinase inhibitor era
Ishida H et al. Am J Hematol, May 2023

Pediatric chronic myeloid leukemia in myeloid blast crisis
Dey B and Dutta A. Autops Case Rep, April 2023

Recent progress in the management of pediatric chronic myeloid leukemia - Review
Shima H. and Shimada H. Int J Hematol, February 2023

Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations - Review
Sembill S et al. Leukemia, January 2023
open access publication

Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicentre experience in Taiwan
Liu HC et al. Br J Cancer, January 2023

Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants
Hoch M et al. Clin Pharmacol Drug Dev, January 2023